Physician profile
Carrie Adele Cain
NPI 1396402905
$4,266.16
in general payments reported to CMS, 2019-2025
32 companies · $2,234 in 2025
The $2,234 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $272 · 2024: $1,761 · 2025: $2,234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,266.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $883.25 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $856.74 | 2023-2025 | |
| Novo Nordisk INC | $517.31 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $300.34 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $256.76 | 2023-2025 | Jardiance, Synjardy, Ofev |
| Amgen INC. | $190.02 | 2024-2025 | Repatha, Otezla, Otezla |
| Exact Sciences Corporation | $148.88 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $125.82 | 2024-2025 | Mounjaro, Zepbound |
| Corium, LLC | $123.14 | 2024-2025 | Azstarys |
| Novartis Pharmaceuticals Corporation | $101.86 | 2025 | |
| Pfizer INC. | $86.94 | 2024-2025 | |
| Esperion Therapeutics, INC. | $77.81 | 2024-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $66.82 | 2024-2025 | Capvaxive, Gardasil 9, Vaxneuvance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $60.53 | 2025 | Caplyta |
| Lundbeck LLC | $45.21 | 2025 | Rexulti |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $39.35 | 2025 | Xyosted |
| Glaxosmithkline, LLC. | $39.14 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Abbott Laboratories | $32.50 | 2025 | Freestyle Libre 3 |
| Supernus Pharmaceuticals, INC. | $31.11 | 2025 | Qelbree |
| Dexcom, INC. | $31.02 | 2023-2024 | Dexcom G6 Transmitter |
| Aimmune Therapeutics, INC. | $30.52 | 2024-2025 | Zenpep |
| Janssen Pharmaceuticals, INC | $29.32 | 2024 | Xarelto |
| Corcept Therapeutics | $28.75 | 2024 | Korlym |
| Eisai INC. | $22.89 | 2024 | |
| Verona Pharma, INC. | $22.03 | 2025 | Ohtuvayre |
| Otsuka America Pharmaceutical, INC. | $21.88 | 2024 | Rexulti |
| Madrigal Pharmaceuticals | $17.90 | 2025 | Rezdiffra |
| Tempus Ai, INC | $16.86 | 2024 | |
| Vertical Pharmaceuticals, LLC | $16.84 | 2025 | Relexxii |
| Takeda Pharmaceuticals U.S.A., INC. | $16.31 | 2024 | Trintellix |
| Currax Pharmaceuticals LLC | $14.93 | 2024 | Contrave |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.38 | 2024 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carrie Cain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.